Patent SG-11201805777Q-A (SG)
Title: Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
Inventor: HUI HO-WAH
IPC: C07D417/14
Filed: 2017-01-06
Abstract: Filing Language: (26) Publication Language: (30) Priority Data: 62/276,756 8 January 2016 (08.01.2016) US ( 84 ) 6 January 2017 (06.01.2017) English English AA Counts W O 20 17 / 120 437 Al BB Form A 1000 2000 100 ° 0 1500- DO Form C 1000 - 500 '- 0 3000 1 2000- 000- 0 cc Form B EE Form 0 1500- FF Form E 1000 500- 0 20 30 Position [°2Theta] (Copper (Cu)) 10 GG FIG. 1 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 July 2017 (13.07.2017) WIPO I PCT (10) International Publication Number WO 2017/120437 Al 1111111111111101110111111111110101111101110111010111111111101111111111111111110111111 (51) International Patent Classification: A61K 31/454 (2006.01) C07D 417/14 (2006.01) C07D 401/04 (2006.01) (21) International Application Number: PCT/US2017/012483 (22) International Filing Date: (71) Applicant: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). (72) Inventors: HUI, Ho-Wah; 10 Heritage Court, Basking Ridge, NJ 07920 (US). PU, Yu; 17 Brentwood Drive, East Hanover, NJ 07936 (US). (74) Agents: BRUNER, Michael, J. et al.; Jones Day, 250 Ve- sey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-02-(2,6-DIOXOPIPERIDIN-3-YL)-1-0X0ISOINDOLIN-5- YL)METHYL)-2,2-DIFLUOROACETAMIDE (57) : Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-y1)-1-ox- oisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereisomer or mixture of stereisomers, pharmaceutically ac- ceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formu- lations and dosage forms for treating, managing, and/or pre- venting cancer are also provided herein. WO 2017/120437 Al 1#11101M011111 11111111MIDE111010111111001EMOVOIS Published: — with international search report (Art. 21(3))